Events

Date: 24 November 2025   Time: 12:00 - 13:00

Location: Room 325, Engineering Building

Seminar Title:

A Tissue Therapy Revolution: Engineering Personalised Skin for Regenerative Medicine

Abstract:

CUTISS AG is leading a transformation in skin surgery through the development of personalised, bioengineered human skin designed to replace traditional autologous grafts. Its flagship innovation, denovoSkin™, is a first-in-class, bi-layered (dermis and epidermis) human skin graft cultivated from a small patient biopsy and matured in a scalable, automated, and fully closed manufacturing platform. In this seminar, Dr Daniela Marino, Co-Founder and CEO of CUTISS AG, will present the scientific and engineering journey from academic research to clinical translation.

Dr Marino will also explore the regulatory, manufacturing, and translational challenges involved in bringing a living tissue therapy to market: navigating orphan-drug designation, scaling up GMP-grade production, developing decentralised manufacturing models, and securing investment to sustain innovation. Beyond skin surgery, the seminar will highlight how CUTISS AG is extending its bioengineering platform towards advanced dermatology, next-generation pigmentation therapies, and tissue regeneration in extreme environments such as aerospace and space health. This seminar will offer valuable insights for engineers, clinicians, and researchers interested in translational bioengineering, regenerative medicine, and biomanufacturing automation — demonstrating how a revolution in tissue therapy begins by re-engineering the process from cell to clinic.

About the speaker:

Dr Daniela Marino, PhD — Co-Founder and Chief Executive Officer, CUTISS AG

Dr Daniela Marino is a pioneering biotechnologist and entrepreneur working at the interface of biology, bioengineering, and clinical innovation. She holds a Masters' degree in Biotechnology from the University of Milan and a PhD from ETH Zurich, where she specialised in vascular biology and stem cell research. Following her doctoral studies, Dr Marino joined the Tissue Biology Research Unit at the University of Zurich, where she advanced from postdoctoral researcher to project manager and project co-leader. During her time at Wyss Zurich, she played a key role in bridging scientific discovery and commercial development within the biomedical innovation ecosystem.

In 2017, building upon promising safety data from early clinical research, she co-founded CUTISS AG to advance the development of denovoSkin™, an autologous, bioengineered human skin designed to improve outcomes for patients suffering from severe burns and skin defects. Under her leadership, CUTISS AG has achieved Orphan Drug Designation in Switzerland and the EU, established a fully automated GMP manufacturing platform, and progressed denovoSkin™ into Phase III clinical trials. Dr Marino has been widely recognised for her contributions to biotechnology and translational research.

She was named Female Innovator of the Year in 2019 and continues to be celebrated as one of Europe's leading voices in regenerative medicine entrepreneurship.

As of today, the company has raised more than $90m, reached readout of Phase 2 and is entering Phase 3. CUTISS AG is scaling its operations and expanding its platform into novel tissue engineering and pigmentation restoration applications, with future ambitions extending to space health and biomedical sustainability. Dr Marino's leadership exemplifies the synergy between scientific rigour, engineering innovation, and entrepreneurial vision, demonstrating how translational bioengineering can redefine standards of care in modern medicine.

https://cutiss.swiss/about-us/

https://www.linkedin.com/in/daniela-marino-3bb35a26/?locale=en_US